FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.567,43 +629,18 (+1,07%)
Atea Pharmaceuticals, Inc. (AVIR)
Dopo ore:
| Chiusura precedente | 3,6900 |
| Aperto | 3,7100 |
| Denaro | 3,6900 x 300 |
| Lettera | 3,7500 x 100 |
| Min-Max giorno | 3,6523 - 3,7200 |
| Intervallo di 52 settimane | 2,7650 - 5,1900 |
| Volume | |
| Media Volume | 390.750 |
| Capitalizzazione | 312,25M |
| Beta (5 anni mensile) | 0,16 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,6300 |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 3,50 |
GlobeNewswireAtea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat and present a business update at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:10 a.m. ET. A live webcast of the pre
- GlobeNewswire
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environmentEnrollment continues in Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of hepatitis C (HCV) with initial results expected in 4Q23Conference call at 4:30 pm ET today BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceutic
- GlobeNewswire
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, August 8, 2023, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2023, and to provide a business update. To access the live conference call, pa
